许多研究人员正在试图寻找可作为阿尔茨海默病（AD）有效治疗的重用药物。最近的几项研究已经强调了作为抗癌药物批准使用的表皮生长因子受体（EGFR）抑制剂作为AD治疗候选药物的潜力。在癌症中，EGFR抑制剂靶向细胞增殖和血管生成，而在AD小鼠模型中的研究表明，EGFR抑制剂可以减轻淀粉样蛋白-β（Aβ）病理和改善认知功能。在本综述中，我们讨论了EGFR在癌症和AD中的不同功能，以及EGFR作为AD疾病的双重分子靶点的潜力。此外，我们描述了抗癌EGFR酪氨酸激酶抑制剂（TKIs）对AD病理的影响以及它们作为AD治疗干预手段的前景。通过总结EGFR在癌症和AD中的生理功能，本综述强调了EGFR作为这些疾病的重要分子靶点的意义。版权所有 © 2023 Choi、Jeong、Kim和Hoe。

Many researchers are attempting to identify drugs that can be repurposed as effective therapies for Alzheimer's disease (AD). Several recent studies have highlighted epidermal growth factor receptor (EGFR) inhibitors approved for use as anti-cancer drugs as potential candidates for repurposing as AD therapeutics. In cancer, EGFR inhibitors target cell proliferation and angiogenesis, and studies in AD mouse models have shown that EGFR inhibitors can attenuate amyloid-beta (Aβ) pathology and improve cognitive function. In this review, we discuss the different functions of EGFR in cancer and AD and the potential of EGFR as a dual molecular target for AD diseases. In addition, we describe the effects of anti-cancer EGFR tyrosine kinase inhibitors (TKIs) on AD pathology and their prospects as therapeutic interventions for AD. By summarizing the physiological functions of EGFR in cancer and AD, this review emphasizes the significance of EGFR as an important molecular target for these diseases.Copyright © 2023 Choi, Jeong, Kim and Hoe.